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Abstract
Dendritic cells (DC) can achieve cross-presentation of naturally-occurring tumor-associated antigens after phagocytosis and
processing of dying tumor cells. They have been used in different clinical settings to vaccinate cancer patients. We have
previously used gamma-irradiated MART-1 expressing melanoma cells as a source of antigens to vaccinate melanoma
patients by injecting irradiated cells with BCG and GM-CSF or to load immature DC and use them as a vaccine. Other clinical
trials have used IFN-gamma activated macrophage killer cells (MAK) to treat cancer patients. However, the clinical use of
MAK has been based on their direct tumoricidal activity rather than on their ability to act as antigen-presenting cells to
stimulate an adaptive antitumor response. Thus, in the present work, we compared the fate of MART-1 after phagocytosis of
gamma-irradiated cells by clinical grade DC or MAK as well as the ability of these cells to cross present MART-1 to CD8
+ T
cells. Using a high affinity antibody against MART-1, 2A9, which specifically stains melanoma tumors, melanoma cell lines
and normal melanocytes, the expression level of MART-1 in melanoma cell lines could be related to their ability to stimulate
IFN-gamma production by a MART-1 specific HLA-A*0201-restricted CD8
+ T cell clone. Confocal microscopy with Alexa
FluorH
647-labelled 2A9 also showed that MART-1 could be detected in tumor cells attached and/or fused to phagocytes and
even inside these cells as early as 1 h and up to 24 h or 48 h after initiation of co-cultures between gamma-irradiated
melanoma cells and MAK or DC, respectively. Interestingly, MART-1 was cross-presented to MART-1 specific T cells by both
MAK and DC co-cultured with melanoma gamma-irradiated cells for different time-points. Thus, naturally occurring MART-1
melanoma antigen can be taken-up from dying melanoma cells into DC or MAK and both cell types can induce specific
CD8
+ T cell cross-presentation thereafter.
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Introduction
Cutaneous melanoma (CM) accounts for 4% of all neoplasia
and it is the tumor with the fastest growing incidence worldwide
[1]. Melanoma tumors are highly resistant to chemotherapy, but
more responsive to immunological treatments. A large variety of
antigens have been associated to CM, such as Melan A/MART-1
[2,3], gp100 [4], Tyrosinase [5], TRP-2 [6], and NY-ESO-1 [7].
MART-1 is a hydrophobic transmembrane protein without
glycosylation sites highly enriched in early melanosomes.
MART-1 is necessary for gp100 function, another antigen
associated to CM, involved in the regulation of melanosome
formation [8]. MART-1 is expressed in skin and retinae
melanocytes and in the majority of melanoma tumors, but it is
absent from other tissues and tumors. It was isolated thanks to the
specific recognition by T lymphocytes of MART-1 derived
peptides, specially in the context of the HLA-A0201 haplotype,
present in tumor infiltrates from melanoma patients [2,3]. Thus,
MART-1 is immunogenic in humans and has been widely
exploited to induce anti-melanoma immunity in patients by means
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peptides either injected with adjuvants and/or pulsed on DC has
been tested in clinical settings, although with very modest
outcomes so far [9–11]. Also, MART-1 specific immune responses
are frequently assessed to monitor the ability of melanoma
vaccines to induce immunity in treated patients [12].
Using whole irradiated tumor cells to load DC could be
preferable to develop DC-based vaccines since melanoma cells
could contribute with known antigens such as MART-1 and
probably unknown antigens. We have used this strategy to
vaccinate melanoma patients with a mixture of gamma-irradiated
melanoma cell lines and BCG, a potent inflammatory adjuvant
[13], and plus GM-CSF to further attract DC to the vaccination
site [14]. We and others have demonstrated in murine models
[15], and in humans [16,17] that when DC engulf gamma-
irradiated melanoma cells, antigens can be cross-presented for the
generation of HLA class I/peptide-complexes, allowing the
induction of specific CTLs. However, in the human, the fate
and immunogenic potential of DC that have phagocytosed dying
tumor cells or their debris remains an open issue.
The use of irradiated allogeneic tumor cells is based on the
paradigm that tumor cells would only trigger MHC-restricted
tumor-specific immunity after being phagocytosed by DC, the
main initiators of immune response able to activate naı ¨ve CD8
+ T
cells [18]. After phagocytosis, DC evolve to a mature phenotype,
diminish their phagocytic ability, express HLA class II and co-
stimulatory molecules on their surface, and acquire the capacity to
present antigens in the appropriate self-HLA context. In parallel,
and through the expression of adequate chemokine receptors, such
as CCR7, DC are able to migrate to the draining lymph nodes to
prime naive lymphocytes and trigger cellular and/or humoral
immunity [19]. Both CD4
+ and CD8
+ naı ¨ve cells can be primed
by DC [18]. CD8
+ T cells can be stimulated after phagocytosis by
a process called cross-presentation that allows exogenous peptides
to be presented in the context of HLA Class I molecules [20].
Some other studies have used non-naturally occurring tumor-
associated antigens such as tumor cells virally transduced with
antigens or apoptotic tumor cells infected with recombinant
viruses encoding melanoma associated antigens [21–24]. Howev-
er, few of these studies have evaluated the cross-presentation of
naturally occurring melanoma antigens taken up from apoptotic/
necrotic tumor cells.
Other phagocytes like macrophages could also be possible
mediators in the induction of antitumor immunity, although their
clinical use has focused only on their tumoricidal activity. Notably,
the ability of human macrophages prepared for clinical use to
cross-present naturally-occurring tumor-associated antigens has
not been investigated, although it has been shown that thiogly-
colate-elicited peritoneal or bone-marrow derived mouse macro-
phages can present efficiently an exogenous antigen (OVA-beads
or OVA-derived peptide) and stimulate naive CD8
+ T cells to
differentiate into OVA-specific memory cells [25,26] Brayer et al
also showed that thioglycolate-elicited peritoneal exudate mouse
macrophages exhibit an enhanced cross-presentation of influenza
hemaglutinin (HA) and OVA-derived peptides with targeted
STAT3 disruption [27]. It has also been shown that thioglycolate-
elicited peritoneal mouse macrophages are more efficient in
inducing cross-presentation following phagocytosis than when
loaded with OVA-derived peptide [28]. More recently, it has been
shown that lymph node resident CD169
+ mouse macrophages are
responsible for early activation of OVA-antigen specific CD8
+ T
cells [29]. Thus, there is no demonstration that clinical grade
human macrophages can efficiently cross-present naturally-occur-
ring tumor antigens and, if so, how it compares with the well-
documented cross-presentation achieved by human DC prepared
for therapeutic use. Of note, when mice were vaccinated with DC
loaded with apoptotic/necrotic B16 cells (DC-Apo/Nec), a tertiary
lymphoid structure was generated at the vaccination site that
contained a wide variety of cell populations, including macro-
phages, polymorphonuclear cells, as well as CD4
+ and CD8
+ T
lymphocytes found together with DC [30]. This suggests that
macrophages could also contribute to the antitumor response
against gamma-irradiated tumor cells locally, or after migration to
the lymph nodes.
Thus, we tested the cross-presentation of human clinical grade
DC and macrophages cultured with gamma-irradiated melanoma
cells as a source of MART-1 antigen to a specific CD8
+ T cell
clone. Using a new mouse high-affinity monoclonal antibody
(mAb) against MART-1, 2A9, we analyzed the presence of
MART-1 within two different human antigen-presenting cells, DC
and IFN-gamma activated macrophages (MAK), after phagocy-
tosis of MART-1 expressing gamma-irradiated melanoma cells at
different time points. We also related this antigen capture to
MART-1 cross-presentation to specific CD8
+ T lymphocytes.
Materials and Methods
Tumor cells
Six melanoma cell lines (MEL-XY1, MEL-XY3, MEL-XX4
[17], MEL-XX5, MEL-XY6, and MEL-XY10) were established
from tumor biopsies from metastatic melanoma patients at the
Instituto Alexander Fleming (Buenos Aires, Argentina). Jau cells
are melanoma cells derived from a metastatic tumor biopsy that
can be cultured for several days in vitro (primary culture). All cell
lines and Jau cells, except MEL-XX4 and MEL-XY10, are
HLA*0201 positive as determined by FACS analysis with a
phycoerythrine (PE)-labeled anti-HLA-A2 monoclonal antibody
(mAb) (clone BB7.2, BD Biosciences, San Jose ´, CA, USA). All
tumor biopsy samples were obtained from melanoma patients who
were enrolled in several clinical trials authorized by the Comite ´d e
Docencia e Investigacio ´n of Instituto Alexander Fleming (Institu-
tional Review Board) and who gave written informed consent.
Cells were cultured as previously described [17].
MART-1 non-expressing breast carcinoma MCF-7 cells [31]
[obtained from the American Tissue Culture Collection (ATCC,
Manassas, USA)] were cultured in DMEM/F12, supplemented
with 100I.U./mL penicillin, 100 mg/mL streptomycin, 2 mM
glutamine, 10 mg/mL insulin, 10% FBS. HLA-A*0201 positive
MART-1 non-expressing breast carcinoma IIB-BR-G cells were
cultured as previously described [32]. MART-1 non-expressing
HT-29 colon carcinoma cells were obtained from the ATCC and
cultured in DMEM supplemented with 2 mM L-glutamine,
3.5 mg/mL sodium carbonate, 4.5 g/L glucose and 10% FBS.
Macrophages and dendritic cells
Human IFN-gamma activated macrophages (termed Macro-
phage Activated Killer, MAK) were a kind gift of Dr J.
Bartholeyns (Immuno-Designed Molecules S.A., Paris, France).
They were obtained as previously described [33].
Human DC were derived from PBMC of buffy-coats obtained
from healthy donors at the Hemotherapy Department of the
Instituto Alexander Fleming as previously described [17]. This
procedure received approval from the Comite ´ de Docencia e
Investigacio ´n of the Instituto Alexander Fleming and healthy
donors gave written informed consent. To induce DC maturation,
2 mg/mL LPS (Lipopolysaccharide from E. coli J5, Sigma, St.
Louis, MO, USA) were added and the cells were further cultured
MART-1 Cross-Presentation by MAK and DC
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CD86 labelling.
MAK and DC phenotypes have been extensively characterized
elsewhere [17,33]. They were both obtained under GMP
conditions identical to those used for clinical trials [34,35].
Anti-MART-1 monoclonal antibodies
MAbs directed against MART-1 were obtained by immunizing
BALB/c ByJ mice (Charles River Laboratories, L’abresle, France)
with purified glutathione-S-transferase (GST)-MART-1 fusion
obtained by cloning MART-1 cDNA isolated from the IIB-
MEL-J melanoma cell line [36] into the pGEX-2T vector (GE
Healthcare, Saclay, France). After ELISA screening for anti-
MART-1 IgG mAbs, two hybridomas, 1F9 and 2A9, were selected
and cloned as previously described [37]. 1F9 and 2A9 mAbs are
IgG1, k as determined by isotype-specific ELISA. Purification of
these antibodies was performed by Protein-A affinity chromatog-
raphy (rProtein A Sepharose
TM fast flow) (GE Healthcare). For
confocal microscopy experiments, the purified 2A9 mAb was
coupled to Alexa Fluor
647 fluorochrome using the Alexa Fluor
647
Protein Labeling Kit (Molecular Probes, Eugene, OR, USA).
Animal used for hybridoma production were handled in compli-
ance with Institutional guidelines and experiments were approved
by the Ethics Committee in Animal Experiment Charles Darwin,
Paris, France.
The affinity constants (Kaff) of 1F9 and 2A9 mAbs for GST-
MART-1 coated onto ELISA plates were determined using the
protocol described by Beatty et al. [38]. Briefly, 96-well ELISA
plates (Nunc, Roskilde, Denmark) were coated overnight at 4uC
with four concentrations (4, 2, 1 and 0.5 mg/mL) of GST-MART-
1 in PBS. Serial three-fold dilutions (from 1.33610
27 down to
2.26610
212 M) of purified 1F9, 2A9 mAbs or of the anti-MART-
1 A103 mAb (Calbiochem-Merck Chemicals, Beeston, United
Kingdom) [39] were then performed in duplicate for each
concentration of GST-MART-1. After incubation for 2 hours at
room temperature, binding was revealed using Alkaline Phospha-
tase (AP)-conjugated goat anti-mouse IgG (Fc specific) antibodies
(1:1,000) (Southern Biotechnologies, Birmingham, AL, USA) for
2 hours at room temperature. O.D.405 nm was measured after
30 minutes incubation at room temperature.
Competition binding assay
A competition assay was performed by ELISA using biotiny-
lated 2A9 mAb and unlabelled 1F9, 2A9 or A103 anti-MART-1
mAbs as competitors. 96-well ELISA plates (Nunc) were coated
with 5 mg/mL purified GST-MART-1 in PBS. Three-fold
dilutions of purified 1F9, 2A9 or A103 mAbs in PBS-Tween
0.05% (starting at 20 mg/mL) were then incubated for 2 hours at
room temperature. After washing, biotinylated 2A9 mAb was
added (700 ng/mL in PBS-Tween 0.05%) and incubated for
2 hours at room temperature. After washing, microplates were
incubated with a streptavidin-horse radish peroxidase (HRP)
solution (Dako, Glostrup, Denmark) for 20 minutes at room
temperature. O.D.450 nm was measured after 30 minutes incuba-
tion at room temperature.
Immunohistochemistry
Melanoma, colon and breast carcinoma biopsies were obtained
from the Instituto Alexander Fleming and from the Pathology
Department, Hospital Interzonal General de Agudos (HIGA-Eva
Pero ´n), Buenos-Aires, Argentina. Immunohistochemistry (IHC)
anonymised sections from melanoma biopsies were also kindly
provided by Pr. Vacher-Lavenu (Department of Pathology of the
Tarnier Unit of Dermatopathology, Cochin Hospital, Paris,
France). Obtention of tumor biopsy samples was authorized by
the Comite ´ de Docencia e Investigacio ´n of Instituto Me ´dico
Especializado Alexander Fleming, in which case patients gave
written informed consent. In case of biopsies from HIGA-Eva
Pero ´n and from Cochin Hospital, since these samples belong to
the Hospital archives and are anonymous, patient’s consent was
not requested by the Bioethics Committee of the HIGA-Eva Pero ´n
and the Ethics Committee from Cochin Hospital. Biopsy
specimens were fixed in 10% neutral buffered formalin, embedded
in paraffin and 4-mm tissue sections were cut and processed for
IHC. Epitope retrieval was performed by incubation in a pressure
cooker or in a water bath with citrate buffer, pH 6.0, for 1 minute
after reaching boiling temperature or at 95uC for 40 minutes,
respectively. After inactivation of endogenous peroxidase, tissue
sections were blocked with normal horse serum (Vectastain Elite
ABC Kit; Vector Laboratories, Burlingame, CA, USA) or with 5%
human AB serum (Biowest, Nuaille ´, France) for 30 min, and
incubated overnight at 4uC with 0.5 mg/mL 2A9 mAb. After
washing, slides were incubated with biotinylated universal
secondary antibodies (Vectastain Elite ABC Kit) or with
biotinylated sheep IgG anti-mouse IgG1 antibodies (The Binding
Site, Birmingham, United Kingdom), followed either by avidin-
biotin complex reagent and peroxidase substrate (VECTOR
NovaRed Substrate Kit; Vector Laboratories) or by streptavidin-
HRP (Dako) followed by AEC substrate (AEC Substrate kit for
Peroxidase, Vector Laboratories). Counterstaining was performed
with 10% hematoxylin. As a negative control, primary antibodies
were omitted or a mouse isotype control [IgG1, k (Southern
Biotechnologies)] was used.
Western Blot of melanoma cell extracts
Melanoma cells were lysed with 50 mM Tris-HCl (pH 7.5),
5 mM EDTA, 150 mM NaCl, 1% NP-40, 0.1% SDS, in presence
of Protease Inhibitor Cocktail (Sigma) for 30 minutes on ice.
Protein extracts were obtained after centrifugation at 8,0006g for
10 minutes at 4uC and total protein concentration was measured
by the Bradford assay. Fifty micrograms protein were fractionated
in 12% SDS-PAGE gels, transferred onto nitrocellulose mem-
branes (Sigma), blocked with 3% dried skim milk in PBS and then
incubated with 2A9 mAb (5 mg/mL) and an anti-b-actin mAb
(clone AC-15) (Sigma) overnight at 4uC. Binding of the mAbs was
revealed using Alkaline Phosphatase (AP)-conjugated goat F(ab)92
anti-mouse IgG(H+L) (Jackson Immunoresearch, West Grove, PA,
USA). Color development substrate was 5-bromo-4-chloro-3-
indolyl-phosphate/nitro blue tetrazolium (NBT/BCIP) (Promega).
MART-1 detection by FACS and confocal microscopy
MART-1 was detected by staining melanoma cells with 2A9
mAb, after fixation with 3% paraformaldehyde (PFA) (Fluka,
Buchs, Switzerland) and permeabilized with 0.05% saponin (PBS-
Sap). 2A9 mAb or an isotype-matched control antibody (Sigma)
(5 mg/mL) were incubated with cells for 1 hour at 4uC in PBS-
Sap. Cells were washed and further incubated with 1/50
secondary R-PE-conjugated F(ab9)2 goat-anti-mouse Ig(H+L)
antibodies (Dako) for 1 hour at 4uC. They were analyzed by flow
cytometry with a FACSCalibur (BD Biosciences) with the
CellQuestPro software (BD Biosciences). Results are indicated as
percentage of positive cells and Mean Fluorescent Intensity (MFI).
For confocal microscopy, cells were grown on 0.1 mg/mL poly-
L-lysine (Sigma) treated coverslips (Knittel Gla ¨ser KN0011879,
Braunschweig, Germany) for 2–3 days at 37uC in a 5% CO2
incubator. After washing, cells were fixed, permeabilized as above
and incubated with Alexafluor
647 coupled 2A9 mAb (2 mg/mL in
PBS-Sap) for 1 hour on ice. After washing, coverslips were
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Merck Chemicals) or with Prolong Gold with Hoechst (Invitrogen
Life Technologies). As controls for the phagocytosis assay, co-
cultures were incubated at 4uC instead of 37uC. Slides were
analyzed with a confocal microscope LSM 510 (Carl Zeiss, Jena,
Germany). Pictures were processed with the AIM or the Zen 2008
Light Edition software (Carl Zeiss).
Induction of IFN-gamma production by co-culture of
melanoma cells and M27 T cell clone
3610
5 MEL-XY3 melanoma cells and M27 cells were co-
cultured (1:1) in 600 mL of AIM-V medium (Invitrogen), in 24-well
plates, overnight at 37uC. The M27 HLA-A*0201-restricted anti-
MART-1 (AAGIGILTV) CTL clone was kindly provided by Dr.
C. Yee (Fred Hutchinson Cancer Research Centre, Seattle, WA,
USA). M27 cells were cultured and expanded as previously
described [40].
Cells were then harvested, centrifuged, and supernatants
collected. Culture supernatants were tested for IFN-gamma
content with BD OptEIA human IFN-gamma ELISA set (BD
Biosciences), following the manufacturer’s recommendations. A
calibration curve was performed for each experiment and the
sample concentration was calculated by log-log regression analysis
using Cembal 2.2 software [17].
Phagocytosis assay
Gamma-irradiated melanoma MEL-XY3 cells (gamma-MEL-
XY3) were generated by 70 Gy gamma irradiation (Siemens
Accelerator, Instituto Alexander Fleming) and frozen under liquid
N2 until use. Apoptosis was assessed by Annexin-V/PI staining
and FACS analysis (BD Biosciences). For MAK phagocytosis
experiments, 50 mL of gamma-MEL-XY3 cells (2610
6/mL) were
deposited onto poly-L-lysine-treated lamellae into a well of a 24
well-tissue culture plate. The same volume of MAK cells [6610
6/
mL] was immediately added and mixed with gamma-MEL-XY3
cells (MAK:gamma-MEL-XY3 cell ratio: 3:1). After 20 minutes
incubation at room temperature, 150 mL of 5% FBS-Iscove’s
Modified Dulbecco’s Medium (IMDM Medium, Invitrogen Life
Technologies)] were added and cells were incubated at 37uC for
different periods of time (1, 3, 6, 24, and 48 hours). Either MAK
cells or MEL-XY3 cells were also deposited on coverslips to be
used as controls in labeling experiments.
Immature DC (iDC) from 5 day-cultures or LPS-maturated DC
(mDC) were harvested and placed [3610
5/mL] into a 24-well
tissue culture plate with AIM-V medium. Gamma-MEL-XY3 cells
were added at a DC/MEL-XY3 ratio of 3:1 for different times (1,
3, 6, 24, and 48 hours). In each case, after incubation, cells were
washed with cold PBS, blocked with PBS-0.1% BSA and stained
either with the anti-CD86-Fluorescein Isothiocyanate (FITC)
(clone B70/B7-2, BD Biosciences) (DC) or with a mixture of
anti-CD14-FITC (clone MWP9)/anti-CD32-FITC (clone FLI8.26)
(BD Biosciences) (MAK).
Cells were then washed, fixed and permeabilized before staining
with Alexafluor
647-2A9 mAb as described above and analyzed by
confocal microscopy. Controls included DC and MAK incubated
with Alexafluor
647-2A9 mAb, or gamma-MEL-XY3 cells incubat-
ed with anti-CD86-FITC or a mixture of anti-CD14/anti-CD32-
FITC mAbs.
Cross-presentation assay
Cross-presentation of MART-1 after DC/MAK phagocytosis
was tested using the M27 HLA- anti-MART-1 T cells. DC were
obtained from highly purified (.98%) CD14
+ monocytes derived
from a HLA A*0201 donor using anti-CD14 microbeads (Miltenyi
Biotec, Germany). Monocytes were differentiated to iDC by 5 days
culture as previously described [17]. HLA A*0201 DC or MAK
(3610
5) were incubated with 10
5 gamma-MEL-XY3, or gamma-
MEL-XY10, or gamma-IIB-BR-G as a negative control, for 3, 6,
24 and 48 hours. Co-cultures were then incubated overnight with
M27 T cell clone (10
5 cells) in AIM-V medium. IFN-gamma
amounts in co-culture supernatants were determined in triplicate
as described above. Positive controls included LPS-treated mDC
loaded for 3 hours at 37uC with 20 mg/mL MART-1 or gp100
peptides plus 3 mg/mL b2-microglobulin or MEL-XY3 live cells.
Other controls included M27 cells incubated alone or with
gamma-MEL-XY3 or gamma-IIB-BR-G at 3, 6, 24 and 48 hours
post-irradiation, and with DC or MAK.
Statistics
Comparisons between IFN-gamma basal levels (M27 clone+-
gamma-irradiated tumor cells) and co-culture-stimulated M27
cells (either with DC:gamma-MEL-XY3 or MAK:gamma-MEL-
XY3) were analyzed using Student’s t-test to determine the p-
values. p,0.05 was considered significant.
Results
Characterization of anti-MART-1 2A9 mAb
1F9 and 2A9 mAbs that bound to GST-MART-1 fusion protein
in ELISA were selected. Competition experiments performed with
GST-MART-1 coated onto ELISA plates and biotinylated 2A9
showed that both antibodies efficiently compete for MART-1
binding, as well as the A103 mAb (Figure 1), an antibody
previously shown to be a binder of a MART-1 epitope (100–110)
located within the C-terminus part of the molecule [41]. Thus,
these mAbs recognize the same epitope or overlapping epitopes
located in the C-terminus part of MART-1. They also exhibited
higher affinity for the GST-MART-1 fusion protein than the A103
mAb, in the nanomolar range, as shown using the ELISA method
developed by Beatty et al [38] (Table 1).
Since the 2A9 mAb exhibited the highest affinity and could be
biotinylated without losing its ability to bind MART-1, as opposed
to 1F9 mAb, all the other experiments were performed with this
antibody. The 2A9 mAb stained MART-1
+ melanoma cells using
indirect IHC. A strong cytoplasmic staining of melanoma cells
could be observed, with discrete punctuate structures in the cytosol
Figure 1. Competition ELISA between anti-MART-1 1F9, 2A9
and A103 mAbs and biotinylated-2A9 mAb. 96-well ELISA plates
were coated with purified GST-MART-1 and incubated with purified 1F9,
2A9 or A103 mAbs (three-fold dilutions in duplicate). Biotinylated-2A9
mAb was then added. A streptavidin-HRP solution was used as
detection reagent. Results shown correspond to one representative
experiment out of three independent assays.
doi:10.1371/journal.pone.0040311.g001
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(Figure 2A) and metastases (Figure 2B), as well as melanocytes
present in epidermis (Figure 2C). No staining of keratinocytes
(Figure 2C) and breast cancer cells (Figure 2D) was detected.
Similarly, the 2A9 mAb did not stain colon carcinoma cells (not
shown).
Melanoma cells with different MART-1 expression elicit
different IFN-gamma production by MART-1 specific M27
T cells
FACS analysis after intracellular immunofluorescence staining
by the 2A9 mAb showed that cells from five different melanoma
cell lines and cells from a primary culture of melanoma (JAU)
differently express MART-1 (Figure 3A). MEL-XY3 cells
strongly express MART-1. MEL-XY6 and MEL-XY1 cells also
markedly express MART-1, but are heterogeneous as the
percentage of stained cells is lower than that of MEL-XY3. Of
note, only 35–40% JAU and MEL-XX5 cells were stained.
Finally, MEL-XX4 cells showed the lowest level of MART-1
expression, both in terms of percentage of labeled cells and MFI.
The breast carcinoma MCF-7 cells did not exhibit any staining
(Figure 3A). As shown in Figure 3B, MART-1 could also be
detected by Western blotting, showing that the 2A9 mAb binds a
linear epitope. MART-1 was detected in MEL-XY1, MEL-XY3,
MEL-XY6 and Jau melanoma cell extracts but not in MEL-XX4
and MEL-XX5 cell extracts. These latter cells exhibited the lowest
percentage of labeled cells in the immunofluorescence assay
(Figure 3A). Finally, MEL-XY1 and MEL-XY3 cells showed the
highest level of MART-1 expression. MART-1 expression in
MEL-XY6 was lower, although these cells were readily stained
(Figure 3A).
The melanoma cell lines were then tested for their ability to
induce IFN-gamma production by the MART-1 specific HLA-
A*0201-restricted M27 T cells. As shown in Figure 3C, cells that
express MART-1 (MEL-XY1, MEL-XY3, and MEL-XY6)
elicited a HLA-A*0201-restricted IFN-gamma production. Of
note, all these cells express HLA-A*0201 to a similar level (data
not shown). Interestingly, cells that showed the highest percentage
of labeled cells in the 2A9 intracellular immunofluorescence assay
(MEL-XY3 and MEL-XY6) elicited the highest IFN-gamma
production. As expected, MEL-XX4 cells did not induce any IFN-
gamma production since these cells are negative for HLA-A*0201
expression (not shown).
No M27 IFN-gamma secretion was observed with the JAU
primary culture cell. This could be due to the fact that only 36% of
these cells express MART-1 and that, in addition, only a low
HLA-A*0201 expression is observed in no more than 60% of the
cells (not shown).
MART-1 can be detected in human dendritic cells and
macrophages after phagocytosis of gamma-irradiated
melanoma cells
We selected MEL-XY3 cells for further experiments since they
exhibited higher MART-1 expression almost uniformly (.90%).
First, permeabilized live and gamma-MEL-XY3 were labeled with
the 2A9-Alexafluor
647 mAb. A characteristic punctuate intracel-
lular pattern of MART-1 expression was detected with the
antibody in both live and gamma-MEL-XY3 (Figure 4, left and
middle panels). HT-29 colon carcinoma cells were negative
(Figure 4, right panel).
We then examined whether MART-1 could be detected into
phagocytes after phagocytosis of gamma-MEL-XY3 cells by MAK
or iDC. Gamma-MEL-XY3 cells are a mixture of apoptotic and
necrotic cells as determined by Annexin V and propidium iodide
staining (Figure S1). As shown in Figure 5A, the 2A9-
Alexafluor
647-labeled cell fragments from gamma-irradiated
MEL-XY3 cells could be detected attached to the cell surface
and inside iDC from 3 hours up to at least 48 hours after initiation
of co-cultures. We estimated the proportion of DC that have
captured some MART-1 labeled material from total DC (%
phagocytosis) to be 10–20% of cells by counting several pictures (at
least 150 cells/time point) (not shown). Lack of phagocytosis was
observed when LPS-mDC were tested in the phagocytosis assay
(,3% phagocytosis) (not shown). When MAK were tested in the
phagocytosis assay (Figure 5B), labeled gamma-irradiated MEL-
XY3 cells were seen in close attachment to the MAK surface at
earlier time points (1–3 hours) and 2A9-Alexafluor
647-labeled
material could be observed inside MAK cells from 3 hours and up
to 24 hours after the initiation of co-cultures. Around 10–15% of
MAK exhibited intracellular MART-1 pink labeling after a
6 hours period of co-culture. This percentage tends to decrease
thereafter, down to around 5% at 24 hours. MAK co-cultures
were analyzed for only 24 hours since after that time they started
dying (not shown). No phagocytosis was observed when DC or
MAK co-cultures were incubated at 4uC (not shown).
Table 1. Kaff determination of anti-MART-1 mAbs.
Antibody Kaff *( M
21)
1F9 1.3260.39610
9
2A9 0.2660.16610
9
A103 3.261.7610
7
*Mean of 24 values (n=4 independent experiments).
doi:10.1371/journal.pone.0040311.t001
Figure 2. Immunohistochemical staining of melanoma tumor
tissues with the 2A9 mAb. 2A9 mAb staining of a primary tumor and
of one metastasis from the same melanoma patient is shown in (A) and
(B), respectively; staining of melanocytes present in epidermis is shown
in (C), while no staining of keratinocytes is observed. Black arrows
indicate melanocytes. No staining is observed with a breast carcinoma
tumor biopsy (D). Original magnification: A and C=10006; B and
D=4006.
doi:10.1371/journal.pone.0040311.g002
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+ T
cells MART-1 captured from gamma-irradiated
melanoma cells
Since MART-1-labeled material could be detected inside
phagocytes from 3 hours up to 48 hours after phagocytosis of
gamma-MEL-XY3 cells, we then investigated whether MART-1
could be cross-presented to specific CD8
+ T cells at different times
after phagocytosis.
As observed in Figure 6, both DC and MAK were able to
induce IFN-gamma production from M27 cells as early as 3 hours
and up to 48 hours after initiation of co-cultures with gamma-
MEL-XY3 cells. In both cases, the amount of IFN-gamma
increased along the co-culture time, suggesting that M27 T cells
are being stimulated more efficiently after longer periods of
antigen processing. However, depending on the MAK co-culture
experiments (n=8), the production of IFN-gamma by MAK
peaked at 24 hours and decreased at 48 hours in two experiments,
likely due to a parallel decrease in MAK viability at that time. Of
note, when the MART-1 expressing HLA-A*0201 negative MEL-
XY10 cells were tested, a strong production of IFN-gamma by the
M27 T cell clone was observed after 48 hours of co-culture with
DC or MAK (data not shown), indicating that the cross-
presentation observed with both DC and MAK cells is not due
to a transfer of peptide loaded onto HLA-A*0201 from melanoma
cells to APC. Gamma-MEL-XY3 cells induced only low IFN-
gamma secretion from M27 cells between 3–48 hours after
irradiation when directly incubated with these latter cells. This
was expected as we previously showed that HLA-A*0201
molecules are progressively lost from the cell surface after
irradiation, impairing gamma-MEL-XY3 ability to directly
stimulate phagocytes with time [17]. Specific HLA-A*0201-
restricted responses were obtained using either LPS–matured
DC loaded with the corresponding peptide or M27 stimulation
with live MEL-XY3 cells. As expected, a lack of response was
observed when an unrelated gp100 peptide was used. Also, only
basal level of IFN-gamma was detected when MART-1 non-
expressing HLA-A*0201 positive IIB-BR-G breast carcinoma cells
were used (Figure 6A and 6B).
Discussion
The generation of a CD8
+ T cell antitumor response requires
the presentation of antigenic peptides on antigen-presenting cells
after capture of antigens at the periphery and migration to the
draining lymph nodes [18]. It needs both naı ¨ve CD4
+ and CD8
+ T
cells to be recruited and stimulated by antigen-presenting cells.
This is achieved by DC that have the extraordinary ability to
stimulate naı ¨ve CD8
+ T cells through a process called cross-
presentation [20] in addition to recruit naı ¨ve CD4
+ T cells. Thus,
immunotherapeutic trials have focused on the manipulation of DC
to trigger an antitumor immune response [42]. Different
vaccination strategies, ranging from ex vivo loading of peptides
onto DC followed by reinfusion [43,44] to in vivo targeting of DC
with antibodies [45–47] or subunits of toxins [48] have been
developed to achieve specific immunity in preclinical models and
clinical studies [11,15,17]. Among such strategies one consists in
the ex-vivo loading onto autologous DC of doxorubicin-treated
[16] or gamma-irradiated melanoma cells as a source of multiple
antigens [15,17,33]. We have previously shown that human iDC
loaded with a mixture of apoptotic/necrotic gamma-irradiated
melanoma cells for 48 hours are able to cross-present MART-1
and gp100 antigens and achieved DC maturation comparable to
LPS stimulation [17]. Several reports have suggested that
apoptotic cells may be critical in processing antigens for cross-
presentation, probably by pre-selection of immunologically
important antigenic determinants [49,50]. Besides, necrotic death
is accompanied with the release of cell fragments and of a variety
of molecules that could trigger an inflammatory microenviron-
ment and give maturation stimuli to DC [51].
Other immunotherapeutic trials have been based on the use of
macrophages. Notably, MAK, i.e., IFN-gamma activated macro-
phages derived from purified peripheral monocytes [35] have been
tested in various clinical settings [52,53]. Although macrophages
are also potent antigen-presenting cells, their clinical use has
focused on their short-term tumoricidal activity. In particular, the
ability of human macrophages prepared for clinical use to cross-
present naturally occurring tumor-associated antigens has not
been investigated. Thus, in the present work, we analyzed whether
Figure 3. Differential MART-1 expression in melanoma cells and production of IFN-gamma by M27 CD8
+ T cells. (A) Intracellular
immunofluorescence was performed with cells from five melanoma cell lines, in melanoma cells from a primary culture (JAU), and MCF7 breast
carcinoma cells. Empty histograms show isotype controls and filled histograms staining with the 2A9 mAb. Percentage of positive cells and MFI are
indicated. (B) The expression of MART-1 in cells from different melanoma cell lines was tested by Western blotting with the 2A9 mAb, using an anti-b-
actin mAb as a loading control. (C) IFN-gamma production by MART-1-specific M27 T cell clone. Melanoma cells and M27 cells were co-cultured
overnight at a 1:1 ratio. Culture supernatants were then tested by ELISA for IFN-gamma content in triplicates. The mean IFN-gamma values (pg/mL
6S.D.) are indicated. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0040311.g003
Figure 4. Intracellular MART-1 detection with 2A9-Alexafluor
647 mAb by confocal microscopy. (A) MEL-XY3 viable cells and (B) gamma-
irradiated MEL-XY3 cells (gamma-MEL-XY3) showed a punctuate pattern of MART-1 expression, presumably staining melanosomes, while HT-29 colon
carcinoma (C) showed no staining. For better visualization, nuclei were stained with Hoechst.
doi:10.1371/journal.pone.0040311.g004
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phages prepared ex vivo can cross-present naturally occurring
tumor-associated antigen (MART-1) after phagocytosis of apo-
ptotic/necrotic melanoma cells and how they compare with
clinical grade DC [33]. Melanoma cell death through gamma-
irradiation occurs by induction of apoptosis and secondary
necrosis, since after 70 Gy irradiation dying cells consist of a
mixture of A+/PI2 and A+/PI+ cells, as we have shown here for
gamma-MEL-XY3 cells (Fig. S1). Firstly, using a high affinity
mAb specific for MART-1, 2A9 that detects MART-1 by IHC,
immunofluorescence and Western Blot in melanoma cells, the
capacity of HLA-A2
+ tumor cells to directly stimulate MART-1
specific CD8 T cells could be related to the expression level of
MART-1. Secondly, after coupling to Alexafluor
647, the 2A9 mAb
was used to follow MART-1 fate in gamma-irradiated MEL-XY3
cells after co-culture with either DC or MAK. MART-1 labeled
material derived from dying cells could be detected both within
DC and MAK at different times after the initiation of co-cultures.
No MART-1 could be detected in co-cultures incubated at 4uC,
indicating that MART-1
+ cell fragments were captured by an
active phagocytosis process (not shown). Thirdly, both DC and
MAK could cross-present MART-1, inducing similar levels of
IFN-gamma production by a HLA-A*0201 restricted CD8 T cell
clone after different times of phagocytosis. In these assays, gamma-
MEL-XY3 cells alone did not present MART-1 significantly
because, as previously shown [17], HLA-A*0201 molecules are
progressively lost from the tumor cell surface during the gamma
irradiation-induced cell death. Overall, clinical-grade MAK could
cross-present MART-1 as efficiently as DC after phagocytosis of
dying melanoma cells, even after a short contact period (3 hours),
based on an in vitro IFN-gamma production read-out. Whether
these cells could also act as antigen cross-presenting cells in vivo
upon re-infusion remains to be established, as the activation with
IFN-gamma makes these cells short-lived [32] and it is unclear
whether they could migrate via afferent lymphatic vessels to
secondary lymphoid structures to prime naive T cells. However,
we have recently found evidence that, in mice vaccinated with DC
loaded with apoptotic/necrotic B16 cells that achieve 80%
protection against B16 challenge, a tertiary lymphoid structure is
found at the vaccination site, with the presence of CD4
+ and
Figure 5. Detection of MART-1 in DC and MAK after phagocytosis of gamma-irradiated MEL-XY3 cells. Co-cultures between gamma-
MEL-XY3 cells and DC (A) or MAK (B) and cell labeling and confocal microscopy were performed as described under Materials and Methods. White
arrows show MART-1 labeled material within DC and MAK.
doi:10.1371/journal.pone.0040311.g005
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+ T cell clone. Cross-presentation assay was performed as described under Materials and
Methods. For co-cultures, a 3:1 ratio iDC (panel A) or MAK (panel B) to gamma-MEL-XY3 target cells was used and incubation was done for the
indicated times. After co-culture, M27 CD8
+ T cells were added and cells were further incubated overnight. Positive controls were either live MEL-XY3
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+ T lymphocytes together with DC as well as macrophages
[30]. Thus, one can hypothesize that, in the human setting, a
similar situation could be found. Local macrophages and DC
could be able to phagocyte dying tumor cells present in the
vaccines, process tumor derived antigens and cross-present them
to specific CD8
+ T cells. Both DC and macrophages could
contribute to the generation of an antitumor immune response.
Furthermore, when BCG and GM-CSF are used as adjuvants
[14], the potent inflammatory stimulus that is induced may
increase the presence of macrophages at the site of vaccination.
Thus, both DC and macrophages loaded with antigens derived
from dying cells could potentially contribute to the induction of
tumor-specific immunity either by priming naive T cells in the
draining lymph nodes and/or by priming effector/memory T cells
in repeatedly vaccinated patients.
Supporting Information
Figure S1 Annexin V and propidium iodide staining of
gamma-MEL-XY3 cells. Live MEL-XY3 cells (A) and gamma-
MEL-XY3 cells (B) at 3, 6, 24, and 48 hours after irradiation were
stained with Annexin V and propidium iodide (PI) and analyzed
by flow cytometry as described under Materials and Methods.
Early apoptotic cells were defined as Annexin V-FITC
+/PI
2,
while necrotic cells were double-positive. 30,000 cells were
analyzed in each case and percentage of early apoptotic and
necrotic cells are indicated in each quadrant. A representative
experiment is shown.
(TIF)
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